Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Reviews in Endocrine and Metabolic Disorders
Published in: Reviews in Endocrine and Metabolic Disorders 3/2006

01-09-2006

The renaissance of insulin pump treatment in childhood type 1 diabetes

Authors: William V. Tamborlane, Karena Swan, Kristin A. Sikes, Amy T. Steffen, Stuart A Weinzimer

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 3/2006

Login to get access

Abstract

Current goals for the treatment of children and adolescents with type 1 diabetes mellitus include achieving near-normal blood sugar levels, minimizing the risk of hypoglycemia, optimizing quality of life, and preventing or delaying long-term microvascular and macrovascular complications. Continuous subcutaneous insulin infusion (CSII), or insulin pump therapy, provides a treatment option that can assist in the attainment of all of these goals in all ages of children. In pediatric patients, CSII has been demonstrated to reduce both glycosylated hemoglobin levels and frequency of severe hypoglycemia, without sacrifices in safety, quality of life, or weight gain, particularly in conjunction with the use of new insulin analogs and improvements in pump technology. Clinical studies of safety and efficacy of CSII in children are reviewed, as well as criteria for patient selection and practical considerations using pump therapy in youth with T1DM.
Literature
1.
Tamborlane WV, Sherwin RS, Genel M, Felig P. Reduction to normal of plasma glucose in juvenile diabetics by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med 1979;300 11:573–8.PubMedCrossRef
2.
Pickup JC, Keen H, Parsons JA, Alberti KG. Continuous subcutaneous insulin infusion: an approach to achieving normoglycemia. Br Med J 1978;1 6107:204–7.PubMedCrossRef
3.
Lauritzen T, Pramming S, Deckert T, Binder C. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia 1983;24 5:326–9.PubMedCrossRef
4.
Tamborlane WV, Sherwin RS, Genel M, Felig P. Outpatient management of juvenile-onset diabetics with a portable subcutaneous insulin infusion pump. Am J Med 1980;68:190–6.PubMedCrossRef
5.
DCCT Research Group. Resource utilization and costs of care in the Diabetes Control and Complications Trial. Diabetes Care 1995;18 11:1468–78.CrossRef
6.
Amiel SA, Tamborlane WV, Sherwin RS. Defective glucose counterregulation after strict glycemic control of insulin dependent diabetes mellitus. N Engl J Med 1987;316:1376–83.PubMedCrossRef
7.
Amiel SA, Sherwin RS, Simonson DC, Tamborlane WV. Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release. Diabetes 1988;37:901–7.PubMedCrossRef
8.
Cryer PE. Iatrogenic hypoglycemia as a cause of hypoglycemia-associated autonomic failure in IDDM: a vicious cycle. Diabetes 1992;41:255–60.PubMedCrossRef
9.
DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial. N Engl J Med 1993;329 14:977–86.CrossRef
10.
The DCCT Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: the diabetes control and complications trial. J Pediatr 1994;125 2:177–88.CrossRef
11.
DCCT/EDIC Research Group. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the diabetes control and complications trial. J Pediatr 2001;139 6:804–12.CrossRef
12.
Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion: a new way to achieve strict metabolic control, decrease severe hypoglycemia and enhance coping in adolescents with type I diabetes. Diabetes Care 1999;22 11:1779–84.PubMedCrossRef
13.
Ahern JA, Boland EA, Doane R, Ahern JJ, Rose P, Vincent M, et al. Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower therapy HbA1c levels across all age groups. Pediatric Diabetes 2002;3 1:10–5.PubMedCrossRef
14.
Maniatis AK, Klingensmith GJ, Slover RH, Mowry CJ, Chase HP. Continuous subcutaneous insulin infusion therapy for children and adolescents: an option for routine diabetes care. Pediatrics 2001;107 2:351–6.PubMedCrossRef
15.
Plotnick LP, Clark LM, Brancati FL, Erlinger T. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Diabetes Care 2003;26 4:1142–46.PubMedCrossRef
16.
Sulli N, Shashaj B. Continuous subcutaneous insulin infusion in children and adolescents with diabetes mellitus: decreased HbA1c with low risk of hypoglycemia. J Pediatr Endocrinol Metab 2003;16 3:393–9.PubMed
17.
Willi SM, Planton J, Egede L, Schwarz S. Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes mellitus. J Pediatr 2003;143 6:796–801.PubMedCrossRef
18.
Liberatore R Jr, Perlman K, Buccino J, Artiles-Sisk A, Daneman D. Continuous insulin infusion pump treatment in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2004;17 2:223–6.PubMed
19.
Mack-Fogg JE, Orlowski CC, Jospe N. Continuous subcutaneous insulin infusion in toddlers and children with type 1 diabetes mellitus is safe and effective. Pediatric Diabetes 2005;6 1:17–21.PubMedCrossRef
20.
Weinzimer SA, Ahern JA, Doyle EA, Vincent MR, Dziura J, Steffen AT, et al. Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report. Pediatrics 2004;114 6:1601–5.PubMedCrossRef
21.
Tubiana-Rufi N, deLonlay P, Bloch J, Czernichow P. Remission of severe hypoglycemic incidents in young diabetic children treated with subcutaneous infusion. Arch Pediatr 1996;3 10:969–76.PubMedCrossRef
22.
Litton J, Rice A, Friedman N, Oden J, Lee MM, Freemark M. Insulin pump therapy in toddlers and pre-school children with type 1 diabetes mellitus. J Pediatr 2002;141 4:490–5.PubMedCrossRef
23.
Shehadeh N, Battelino T, Galatzer A, Naveh T, Hadash A, de Vries L, et al. Insulin pump therapy for 1–6 year old children with type 1 diabetes. Isr Med Assoc J 2004;6 5:284–6.PubMed
24.
Springer D, Dziura J, Tamborlane WV, Steffen AT, Ahern JH, Vincent M, Weinzimer SA. Optimal control of type 1 diabetes in youth receiving intensive treatment. J Pediatr 2006;149:227–32.PubMedCrossRef
25.
The DCCT Research Group. The absence of a glycemic threshold for the development of long-term complications the prospective of the diabetes control and complications trial. Diabetes 1996;45:1289–98.CrossRef
26.
de Beaufort CE, Houtzagers CM, Bruining GJ, Aarsen RS, den Boer NC, Grose WF, et al. Continuous subcutaneous insulin infusion (CSII) versus conventional injection therapy in newly diagnosed diabetic children: two-year follow-up of a randomized, prospective trial. Diabet Med 1989;6 9:766–71.PubMedCrossRef
27.
Weintrob N, Benzaquen H, Galatzar A, Shalitin S, Lazar L, Fayman G, et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. Pediatrics 2003;112 3 Pt 1:559–64.PubMedCrossRef
28.
Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, Kapitza C, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53 6:1614–20.PubMedCrossRef
29.
Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49 12:2142–8.PubMedCrossRef
30.
Kaplan W, Rodriguez LM, Smith OE, Haymond MW, Heptulla RA. Effects of mixing glargine and short-acting insulin analogs on glucose control. Diabetes Care 2004;27:2739–40.PubMedCrossRef
31.
Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K, Pediatric Study Group of Insulin Glargine. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002;15 4:369–76.PubMed
32.
Murphy NP, Keane SM, Ong KK, Ford-Adams M, Edge JA, Acerini CL, et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003;26 3:799–804.PubMedCrossRef
33.
White NH, Tamborlane W, Ususkin K. Less variability in blood glucose values with insulin glargine vs intermediate-acting insulin (NPH or Lente) in adolescents with T1DM. Diabetes 2006;55 Suppl 1:A138.
34.
Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004;27 7:1554–8.PubMedCrossRef
35.
Wilson DM, Buckingham BA, Kunselman EL, Sullivan MM, Paguntalan HU, Gittelman SE. A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes. Diabetes Care 2005;28 1:15–9.PubMedCrossRef
36.
Di Meglio LA, Pottorff TM, Boyd SR, France L, Fineberg N, Eugster EA. A randomized, controlled study of insulin pump therapy in diabetic preschoolers. J Pediatr 2004;145 3:380–4.CrossRef
37.
Fox LA, Buckloh LM, Smith SD, Wysocki T, Mauras N. A randomized controlled trial of insulin pump therapy in young children with type 1 diabetes. Diabetes Care 2005;28:1277–81.PubMedCrossRef
38.
Jeha GS. Karaviti LP. Anderson B. Smith EO. Donaldson S. McGirk TS. Haymond MW. Insulin pump therapy in preschool children with type 1 diabetes mellitus improves glycemic control and decreases glucose excursions and the risk of hypoglycemia. Diabetes Technol Ther 2005;7:876–84.PubMedCrossRef
39.
The DirecNet Study Group. Impact of exercise on overnight glycemic control in children with type 1 diabetes. J Pediatr 2005;147:528–34.CrossRef
40.
The DirecNet Study Group. The effects of aerobic exercise on glucose and counter-regulatory hormone levels in children with type 1 diabetes. Diabetes Care 2006;29:20–5.CrossRef
41.
The Diabetes Research in Children Network (DirecNet) Study Group. Prevention of hypoglycemia during exercise in children with type 1 diabetes by suspending basal insulin. Diabetes Care 2006;29:2200–4.CrossRef
42.
Burdick J, Chase HP, Slover RH, Knievel K, Scrimgeour L, Maniatis AK, et al. Missed insulin meal boluses and elevated hemoglobin A1c levels in children receiving insulin pump therapy. Pediatrics 2004;113 3 Pt 1:e221–4.PubMedCrossRef
43.
Danne T, Battelino T, Kordonouri O, Hanas R, Klinkert C, Ludvigsson J, et al. A cross-sectional international survey of continuous subcutaneous insulin infusion in 377 children and adolescents with type 1 diabetes mellitus from 10 countries. Pediatric Diabetes 2005;6:193–8.PubMedCrossRef
44.
Sullivan-Bolyai S, Knafl K, Tamborlane W, Grey M. Parent’s reflections on managing their children’s diabetes with insulin pumps. J Nursing Scholarsh 2004;36 4:316–23.CrossRef
45.
Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. CSII: a “new” way to achieve strict metabolic control, decrease severe hypoglycemia and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999;22:1779–84.PubMedCrossRef
46.
Low KG, Massa L, Lehman D, Olshan JS. Insulin pump use in young adolescents with type 1 diabetes: a descriptive study. Pediatric Diabetes 2005;6 1:22–31.PubMedCrossRef
47.
Tamborlane WV, Fredrickson L. Insulin pump therapy of childhood diabetes: guidelines for us. Treat Endocrinol 2003;2:11–21.PubMedCrossRef
48.
Ahern JA, Ramchandani N, Cooper J, Himmel A, Silver D, Tamborlane WV. Using a primary nurse manager to implement DCCT recommendations in a large pediatric program. Diabetes Educ 2000;26 6:990–4.PubMed
49.
Melzer SM, Richards GE, Covington ML. Reimbursement and costs of pediatric ambulatory diabetes care by using the resource-based relative value scale: is multidisciplinary care financially viable? Pediatric Diabetes 2004;5 3:133–42.PubMedCrossRef
50.
Boland E, Monsod T, Brandt CA, Fernando S, DeLucia M, Tamborlane WV. Limitations of conventional methods of self-monitoring of blood glucose: Lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care 2001;24:1858–62.PubMedCrossRef
51.
Diabetes Research in Children Network (DirecNet) Study Group. The accuracy of the CGMS in children with type 1 diabetes: results of the diabetes research in children network (DirecNet) accuracy study. Diabetes Technol Ther 2003;5 5:781–9.CrossRef
52.
Diabetes Research in Children Network (DirecNet) Study Group. The accuracy of the GlucoWatch G2 biographer in children with type 1 diabetes: results of the diabetes research in children network (DirecNet) accuracy study. Diabetes Technol Ther 2003;5 5:791–800.CrossRef
53.
Diabetes Research in Children Network (DirecNet) Study Group. A multicenter study of the accuracy of the One Touch Ultra home glucose meter in children with type 1 diabetes. Diabetes Technol Ther 2003;5 6:933–41.CrossRef
54.
The DirecNet Study Group. Accuracy of the modified Continuous Glucose Monitoring System (CGMS) sensor in an outpatient setting: results from a diabetes research in children network (DirecNet) study. Diabetes Technol Ther 2005;7 1:109–14.CrossRef
55.
DirecNet Study Group. Accuracy of the FreeStyle Navigator continuous glucose monitoring system in children with T1DM. Diabetes 2006;55 Suppl 1:A91–2.
56.
Weinzimer SA, Steil GM, Kurtz N, Swan KL, Tamborlane WV. Automated feedback-controlled insulin delivery in children with type 1 diabetes mellitus: a preliminary report. Diabetes 2006;55 Suppl 1:A102.
Metadata
Title
The renaissance of insulin pump treatment in childhood type 1 diabetes
Authors
William V. Tamborlane
Karena Swan
Kristin A. Sikes
Amy T. Steffen
Stuart A Weinzimer
Publication date
01-09-2006
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 3/2006
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-006-9018-9

Other articles of this Issue 3/2006

Reviews in Endocrine and Metabolic Disorders 3/2006 Go to the issue

OriginalPaper

Adiponectin and leptin: Potential tools in the differential diagnosis of pediatric diabetes?

OriginalPaper

Insulin resistance in children and adolescents

OriginalPaper

Cardiovascular disease risk in youth with diabetes mellitus

OriginalPaper

Prevention strategies for type 1 diabetes

OriginalPaper

The changing spectrum of diabetes in Mexican American youth

ReviewPaper

Monogenic diabetes in children and young adults: Challenges for researcher, clinician and patient
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits